Evidence map›Paper›PMID 40076987›Full record

ReviewInternational journal of molecular sciences2025

Managing a Burning Face: Clinical Manifestations and Therapeutic Approaches for Neurogenic Rosacea.

Gabriel Aedo, Marco Chahuán, Elsa Gatica, Isabel Herrera, Luis Felipe Parada, Alvaro Seguel, Nigel P Murray, Sócrates Aedo, Diego Aragón-Caqueo

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gabriel AedoFacultad de Ciencias Medicas, Universidad de Santiago de Chile, Santiago 8320000, Chile.
Marco ChahuánFacultad de Ciencias Medicas, Universidad de Santiago de Chile, Santiago 8320000, Chile.ORCID 0000-0001-9493-3941
Elsa GaticaFacultad de Ciencias Medicas, Universidad de Santiago de Chile, Santiago 8320000, Chile.
Isabel HerreraFacultad de Ciencias Medicas, Universidad de Santiago de Chile, Santiago 8320000, Chile.
Luis Felipe ParadaFacultad de Ciencias Medicas, Universidad de Santiago de Chile, Santiago 8320000, Chile.
Alvaro SeguelFacultad de Ciencias Medicas, Universidad de Santiago de Chile, Santiago 8320000, Chile.
Nigel P MurrayFacultad de Medicina, Universidad Finis Terrae, Santiago 7501015, Chile.
Sócrates AedoFacultad de Medicina, Universidad Finis Terrae, Santiago 7501015, Chile.ORCID 0000-0001-5567-3374
Diego Aragón-CaqueoEscuela de Medicina, Universidad de Tarapacá, Arica 1000000, Chile.ORCID 0000-0001-7233-960X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rosacea is a common chronic inflammatory condition primarily affecting middle-aged women. It presents with flushing, erythema, telangiectasia, papules, pustules, phymatous changes, and ocular involvement. Although typically grouped into four subtypes-erythematotelangiectatic, papulopustular, ocular, and phymatous-overlapping features often favor a phenotypic diagnostic approach. Neurogenic rosacea (NR) has emerged as a distinct subgroup featuring distinguishing features such as peripheral facial erythema, severe burning and stinging sensations, and resistance to standard rosacea therapies. Recent insights into the pathophysiology of NR propose neural dysregulation as the main driver of the condition. Specifically, the activation of TRP channels at cutaneous sensory nerve endings in the dermis triggers the release of vasoactive peptides, driving neuroinflammation and resulting in burning and stinging. Additionally, there is a marked association with neuropsychiatric comorbidities, which would further mediate the pathogenesis of the condition. In line with this pathophysiological model, NR often fails to respond to conventional rosacea treatments. Instead, patients benefit more from antidepressants and neuroleptic agents that help modulate neuronal activity and alleviate symptoms. This review explores and summarizes the scientific evidence regarding the new insights on disease pathogenesis, clinical manifestations, and proposed treatments for NR.

Indexed as

RosaceaAntidepressive AgentsFaceHumansAntidepressive Agentsneurogenic inflammationneurogenic rosacearefractory erythemarosacea

Identifiers

PMID40076987
PMCPMC11901027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.